Essity stock (SE0009922164): Strategic review of Consumer Tissue segment signals potential re-rating

Essity, the Swedish hygiene and health company, is undergoing a strategic review of its Consumer Tissue segment, a move that has drawn cautiously positive commentary from equity analysts. The announcement represents a potential inflection point for the stock, which has traded at depressed valuations in recent months.

According to Ålandsbanken as of May 2026, the bank maintains a positive outlook on Essity following the Capital Markets Day announcement. Analysts at the institution noted that while the stock is trading at historically low levels, a potential re-rating could occur if the Consumer Tissue segment is divested. The bank's research team stated: "We view the announcement as positive for the stock over time, although the market likely wants to see more concrete steps and terms before a major re-evaluation takes place."

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Essity: core business model

Essity operates as a global hygiene and health company with three primary business segments: Consumer Tissue, Professional Hygiene, and Health & Medical. The company manufactures and distributes tissue products, incontinence care, and medical devices across more than 150 countries. Consumer Tissue, which is now under strategic review, represents a significant portion of the company's portfolio and includes branded products sold through retail channels.

The Professional Hygiene segment serves commercial customers including offices, restaurants, and healthcare facilities. The Health & Medical segment focuses on specialized products for medical and healthcare applications. This diversified portfolio positions Essity as a major player in the global hygiene sector, with exposure to both developed and emerging markets.

Main revenue and product drivers for Essity

Consumer Tissue products, including toilet paper and paper towels, form a substantial revenue base but face margin pressures from raw material costs and competitive pricing. Professional Hygiene solutions generate recurring revenue from institutional customers with long-term contracts. The Health & Medical segment, though smaller, offers higher-margin opportunities in specialized healthcare applications.

The strategic review of Consumer Tissue signals management's recognition that this segment may benefit from standalone operations or alternative ownership structures. Potential divestiture could unlock value by allowing the remaining business to focus on higher-margin Professional Hygiene and Health & Medical segments, which typically command better pricing power and customer retention.

Recent insider activity and market signals

Anna Sävinger Åslund, Senior Vice President of Group Human Resources at Essity, purchased 4,000 Class B shares on May 8, 2026, according to the Swedish Financial Supervisory Authority's insider register as of May 8, 2026. The shares were purchased at SEK 249.32 each, representing a total transaction value of approximately SEK 997,300. Following this transaction, Sävinger Åslund holds 18,945 shares in Essity.

Insider purchases by senior executives, while not guarantees of future performance, can signal management confidence in the company's strategic direction and valuation levels. The timing of this purchase, occurring shortly after the Capital Markets Day announcement, may reflect positive sentiment regarding the potential outcomes of the Consumer Tissue review.

Conclusion

Essity's strategic review of its Consumer Tissue segment represents a potential turning point for the company and its shareholders. The announcement has attracted analyst attention, with Ålandsbanken maintaining a positive outlook while acknowledging that concrete details on any divestiture will be necessary to drive a significant re-rating. Recent insider purchasing activity by senior management suggests confidence in the company's strategic direction. US investors with exposure to the hygiene and health sector may monitor developments closely as management provides further clarity on the review's outcomes and timeline.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.